uploads/2018/11/ALXN2.png

Analyzing Alexion Pharmaceuticals’ Product Performance

By

Updated

Soliris

Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma. Total Soliris sales increased from $755.4 million in the third quarter of 2017 to $888.0 million in the latest quarter. Its US sales increased from $307.6 million in the third quarter of 2017 to $404.5 million in the latest quarter. Its Europe sales increased from $248.4 million in the third quarter of 2017 to $262.1 million in the latest quarter.

Article continues below advertisement

Strensiq

Total Strensiq sales were $113.2 million in the third quarter of 2018 as compared with $87.0 million in the year-ago period. Its US sales increased from $70.6 million in the third quarter of 2017 to $86.6 million in the latest quarter. Strensiq sales in Europe increased from $9.6 million in the third quarter of 2017 to $16.6 million in the latest quarter.

Kanuma

Total sales of Alexion’s Kanuma increased from $16.4 million in the third quarter of 2017 to $25.3 million in the third quarter of 2018. Its US sales increased from $11.4 million in the third quarter of 2017 to $13.7 million in the latest quarter. Kanuma sales in Europe also increased from $3.6 million in the third quarter of 2017 to $4.7 million in the third quarter of 2018.

Its cash per share stands at $6.89. In comparison, the cash per share of peers Abbott Laboratories (ABT), Amgen (AMGN), and Johnson & Johnson (JNJ) stands at $4.31, $44.83, and $7.21, respectively.

We’ll take a look at Alexion Pharmaceuticals’ operational performance in the next part.

Advertisement

More From Market Realist